Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P689: UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapyECCO '18 Vienna
Year: 2018
Authors:

H. Gordon1*, R. Gadhok1, A. Ibarra1,2, J.O. Lindsay1,3

1Royal London Hospital, Gastroenterology, London, UK, 2Barth Health, London, UK, 3The Blizard Institute, Centre for Immunology, Barts and the London School of Medicine, London, UK

P690: Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational studyECCO '18 Vienna
Year: 2018
Authors:

S. Berends1,2*, A. Strik2, J. Jansen3, N. de Boer4, J. Brandse4, G. D'Haens2, R. Mathôt1, M. Löwenberg2

1Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, The Netherlands, 2Academic Medical Center (AMC), Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 4VU University Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands

P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52ECCO '18 Vienna
Year: 2018
Authors:

D. García-Olmo1, J. Panés2*, N. Brayshaw3, M.P. Richard4, C. Agboton5

1Faculty of Medicine, Autonomous University of Madrid, Department of Surgery, Madrid, Spain, 2Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Gastroenterology Department, Barcelona, Spain, 3Takeda Pharmaceuticals International, London, UK, 4TiGenix S.A.U., Tres Cantos, Madrid, Spain, 5Takeda Pharmaceuticals International AG, Zurich, Switzerland

P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic reviewECCO '18 Vienna
Year: 2018
Authors:

J.-F. Colombel1*, R. Ungaro1, S. Aggarwal2, O. Topaloglu2, M. Skup3, W.-J. Lee3

1Icahn School of Medicine at Mount Sinai, New York, USA, 2NOVEL Health Strategies, Bethesda, USA, 3AbbVie Inc., North Chicago, USA

P693: Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?ECCO '18 Vienna
Year: 2018
Authors:

A. Walsh1, A. Kormilitzin2, C. Hinds3, V. Sexton4, J. Wilson1, O. Brain1*, S. Keshav1, H. Uhlig1, J. Geddes4, G. Goodwin4, M. Peters5, G. Collins6, S. Travis1

1John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, UK, 2Mathematical Institute, Oxford, UK, 3Big Data Institute, Oxford, UK, 4University of Oxford, Psychiatry Department, Oxford, UK, 5University of Oxford, Nuffield Department of Population Health, Oxford, UK, 6University of Oxford, Centre for Statistics in Medicine, Oxford, UK

P694: Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomesECCO '18 Vienna
Year: 2018
Authors:

A. Ilias1*, K. Szanto2, L. Gonczi1, Z. Kurti1, P.A. Golovics3, E. Schafer3, K. Farkas2, T. Szamosi3, Z. Szepes2, T. Molnar2, A. Vincze4, P.L. Lakatos1,5

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2University of Szeged, First Department of Internal Medicine, Szeged, Hungary, 3Military Hospital – State Health Centre, Gastroenterology Unit, Budapest, Hungary, 4University of Pécs, 1st Department of Medicine, Pecs, Hungary, 5Mcgill University Health Center, Department of Gastroenterology, Montreal, Canada

P695: Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism?ECCO '18 Vienna
Year: 2018
Authors:

G. Novacek1*, S. Tonko1, A. Sobala1, H. Tilg2, W. Petritsch3, W. Reinisch1, A. Mayer4, T. Haas5, O. Ludwiczek6, T. Feichtenschlager7, H. Fuchssteiner8, P. Steiner9, H. Vogelsang1, W. Miehsler10, R. Platzer11, W. Tillinger12, A. Schmid13, B. Blaha14, H. Herkner15

1Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria, 2Medical University of Innsbruck, Department of Internal Medicine I, Innsbruck, Austria, 3Medical University of Graz, Department of Gastroenterology and Hepatology, Graz, Austria, 4Universitätsklinikum St. Pölten, Department of Internal Medicine II, St. Pölten, Austria, 5Darmpraxis Salzburg, Salzburg, Austria, 6Hospital Hall in Tirol, Department of Internal Medicine, Hall in Tirol, Austria, 7Hospital Rudolfstiftung, Department of Internal Medicine IV, Vienna, Austria, 8Hospital Elisabethinen Linz, Department of Internal Medicine IV, Linz, Austria, 9Hospital Wels-Grieskirchen, Department of Internal Medicine I, Wels, Austria, 10Hospital Barmherzige Brüder Salzburg, Department of Internal Medicine, Salzburg, Austria, 11Hospital Wiener Neustadt, Department of Internal Medicine I, Wiener Neustadt, Austria, 12Hartmannspital, Department of Internal Medicine, Vienna, Austria, 13Danube Hospital, Department of Internal Medicine 2, Vienna, Austria, 14Wilheminenspital der Stadt Wien, Department of Internal Medicine 4, Vienna, Austria, 15Medical University of Vienna, Department of Emergency Medicine, Vienna, Austria

P696: Faecal microbiota transplantation in ultra-refractory ulcerative colitis: Retrospective analysis in a tertiary care centreECCO '18 Vienna
Year: 2018
Authors:

A. Guerrero García1*, A. Flores de Miguel1, E. Sánchez Rodríguez1, R. Ríos León1, G. Roy Ariño2, R. Del Campo Moreno3, A. Albillos Martínez1, A. López-Sanromán1

1Ramon y Cajal, Gastroenterology and Hepatology, Madrid, Spain, 2Ramon y Cajal, Inmunology, Madrid, Spain, 3Ramon y Cajal, Microbiology, Madrid, Spain

P697: Thiopurines vs. anti-TNFa for the prevention of postoperative recurrence in Crohn’s disease—a meta-analysisECCO '18 Vienna
Year: 2018
Authors:

E.M.J. Beelen1*, B. Oldenburg2, A.E. van der Meulen-de Jong3, C.I.J. Ponsioen4, G. Dijkstra5, M.J. Pierik6, F. Hoentjen7, N.K.H. de Boer8, N.S. Erler9, C.J. van der Woude1, A.C. de Vries1

1Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands, 3Leiden University Medical Center, Department of Gastroenteorlogy and Hepatology, Leiden, The Netherlands, 4Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 5University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 6Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, The Netherlands, 7Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands, 8VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 9Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands

P698: Early dose optimisation in non-responders to golimumab induction treatment for ulcerative colitis is supported by pharmacokinetic dataECCO '18 Vienna
Year: 2018
Authors:

G. Philip1, C. Marano2, J. Adedokun2, R. Melsheimer3, F. Cornillie4*

1Merck & Co., Inc., Kenilworth, USA, 2Janssen Research and Development, LLC, Spring House, PA, USA, 3Janssen Biologics BV, Leiden, The Netherlands, 4Merck Sharpe and Dohme, Kriens, Switzerland

P699: Radiologic response reduces the risk of small-bowel surgery in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Hallé1*, M. Azahaf1, N. Duveau2, M. Nachury1, J. Branche1, R. Gerard1, P. Wils1, P. Desreumaux1, O. Ernst1, B. Pariente1

1Hopital Claude Huriez, Lille, France, 2Hopital de Roubaix, Roubaix, France

P700: A high CRP before surgery and early medical prophylaxis predict postoperative endoscopic Crohn’s disease recurrenceECCO '18 Vienna
Year: 2018
Authors:

S. Sooben1, L. Thin1*, S. Picardo2, B. Mackinnon3, J. Ryan4, M.H. Wallace4,5

1Fiona Stanley Hospital, Department of Gastroenterology, Perth, Australia, 2Royal Perth Hospital, Department of Gastroenterology, Perth, Australia, 3Insitute of Immunology and Infectious Diseases, Murdoch University, Statistics, Perth, Australia, 4Fiona Stanley hospital, Colorectal surgery, Perth, Australia, 5University of Western Australia, School of Medicine and Pharmacology, Perth, Australia

P701: Quality of life of patients with inflammatory bowel diseases who live with an ostomy: Results of a French national surveyECCO '18 Vienna
Year: 2018
Authors:

G. Pineton de Chambrun1*, M. Liberatore2, A. Buisson2, P. Blanc1, A. Olympie2

1Montpellier University Hospital, Gastroenterology, Montpellier, France, 2Association François Aupetit, Paris, France

P702: Head-to-head comparison of biological drugs in the treatment of ulcerative colitis: Suggestions from a real-life, inception cohort, single-centre study on consecutive post-marketing treatmentsECCO '18 Vienna
Year: 2018
Authors:

A. Cassinotti1, N. Mezzina1*, A. Massari1, S. Grillo2, S. Ardizzone1

1ASST Fatebenefratelli Sacco, DIBIC “L. Sacco” University of Milan, Gastrointestinal Unit, Milan, Italy, 2University Hospital of Parma, Department of Gastroenterology and Digestive Endoscopy, Parma, Italy

P703: Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

P.G. Kotze*, C. Ma, A. Almutairdi, A. Al-Damarki, S. Devlin, G. Kaplan, C. Seow, K. Novak, C. Lu, J. Ferraz, M. Stewart, M. Buresi, M. Mathivanan, H. Jijon, J. Heatherington, M.-L. Martin, R. Panaccione

University of Calgary, IBD unit, division of Gastroenterology and Hepatology, Calgary, Canada

P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

B. Verstockt1,2*, M. Noman1, I. Aerden1, M. Peeters3, E. Brouwers3, V. Ballet1, L. Vandersmissen1,3, G. Van Assche1,2, A. Gils3, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD populationECCO '18 Vienna
Year: 2018
Authors:

M.L. Hoivik1*, L.C. Buer1,2, N. Bolstad3, B. Moum1,2, A.W. Medhus1

1Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 2University of Oslo, Faculty of Medicine, Oslo, Norway, 3Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway

P706: Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapyECCO '18 Vienna
Year: 2018
Authors:

J. Kovacs1*, B. Kadleckova2, L. Gombosova3, L. Novotna4, E. Barlova4, J. Lucenincova5, P. Mikus6, M. Zakuciova3, Z. Zelinkova1

1St Michael`s Hospital, Department of Gastroenterology, Bratislava, Slovakia, 2Assiduo, IBD Center, Bratislava, Slovakia, 3University Hospital Louis Pasteur, 1st Department of Internal Medicine, Kosice, Slovakia, 4University Hospital Louis Pasteur, Department of Laboratory Medicine, Bratislava, Slovakia, 5St Michael`s Hospital, Department of Biochemistry, Bratislava, Slovakia, 6Comenius University, Faculty of Pharmacy, Bratislava, Slovakia

P707: Increasing abundance of faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn’s disease: A longitudinal studyECCO '18 Vienna
Year: 2018
Authors:

O. Björkqvist1*, D. Repsilber2, M. Seifert3, L. Engstrand3, I. Rangel2, J. Halfvarson2

1Örebro Universitet, School of Medical Sciences, Örebro Universitet, Sweden, 2Örebro Universitet, Örebro, Sweden, 3Karolinska Institutet, Microbiology, Tumor and Cell Biology, Stockholm, Sweden

P708: Home-based infusion therapy for biologic agent administration as a therapeutic option for patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Madden, S. S. R. Pulusu*, I. Lawrance

Centre for Inflammatory Bowel Disease, St John of God Subiaco Hospital, Perth, Australia